359 related articles for article (PubMed ID: 25687208)
1. Vulval Crohn's disease: a clinical study of 22 patients.
Laftah Z; Bailey C; Zaheri S; Setterfield J; Fuller LC; Lewis F
J Crohns Colitis; 2015 Apr; 9(4):318-25. PubMed ID: 25687208
[TBL] [Abstract][Full Text] [Related]
2. Crohn's disease of the vulva: A prospective study.
Bhoyrul B; Lyon C
J Gastroenterol Hepatol; 2018 Dec; 33(12):1969-1974. PubMed ID: 29845642
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience and diagnostic algorithm of vulval Crohn's disease.
Boxhoorn L; Stoof TJ; de Meij T; Hoentjen F; Oldenburg B; Bouma G; Löwenberg M; van Bodegraven AA; de Boer NKH;
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):838-843. PubMed ID: 28430699
[TBL] [Abstract][Full Text] [Related]
4. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
Lakatos PL
Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
Matsumoto T; Motoya S; Watanabe K; Hisamatsu T; Nakase H; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
J Crohns Colitis; 2016 Nov; 10(11):1259-1266. PubMed ID: 27566367
[TBL] [Abstract][Full Text] [Related]
7. Treatment of vulval Crohn's disease with infliximab.
Preston PW; Hudson N; Lewis FM
Clin Exp Dermatol; 2006 May; 31(3):378-80. PubMed ID: 16681581
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
[TBL] [Abstract][Full Text] [Related]
9. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
11. Vulvar swelling as the first presentation of Crohn's disease in children-A report of three cases.
Ahad T; Riley A; Martindale E; von Bremen B; Owen C
Pediatr Dermatol; 2018 Jan; 35(1):e1-e4. PubMed ID: 29159956
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
14. [Severe lymphopenia in a patient with Crohn's disease].
Monasterio C; Kreisel W; Hasselblatt P
Internist (Berl); 2018 Aug; 59(8):857-860. PubMed ID: 29356833
[TBL] [Abstract][Full Text] [Related]
15. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
[TBL] [Abstract][Full Text] [Related]
16. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
[TBL] [Abstract][Full Text] [Related]
17. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond?
Fiorino G; Danese S
J Crohns Colitis; 2016 Nov; 10(11):1257-1258. PubMed ID: 27389085
[No Abstract] [Full Text] [Related]
19. Crohn's disease of the vulva.
Barret M; de Parades V; Battistella M; Sokol H; Lemarchand N; Marteau P
J Crohns Colitis; 2014 Jul; 8(7):563-70. PubMed ID: 24252167
[TBL] [Abstract][Full Text] [Related]
20. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
